Hospital needs volunteers for stroke drug study

Patients who have attended the RUH within 48 hours of an ischaemic stroke can take part in the study

Hospital researchers are supporting a study looking at whether a new drug can help lower the risk of reoccurring strokes.

The Royal United Hospitals (RUH) Bath NHS Foundation Trust said it was taking part in the Librexia study, which is investigating if an anticoagulant known as Milvexian could reduce the risk of future ischaemic stroke in existing patients.

Participants must be aged 40 or above and have been to Royal United Hospitals within 48 hours of an ischaemic stroke or transient ischaemic attack, the trust said.

Kelly Spencer, head of research operations at the RUH, said the study could produce a "really positive outcome".

Ischaemic strokes happen when a blockage cuts off blood supply to part of the brain, killing brain cells.

They can lead to speech and visual disturbance, as well as a numbness or weakness in the face, arms and legs.

A transient ischaemic attack is caused by a temporary disruption in the blood supply to part of the brain, causing sudden symptoms similar to a stroke.

'Better care'

Milvexian thins the blood, helping to reduce the risk of blood clots forming in the bloodstream, the trust said.

It said those participating in the study would be randomly assigned to receive either Milvexian or a placebo, in addition to standard medications suggested by their doctor.

Patients are then seen at the RUH every 13 weeks and for assessments, including blood tests and tests on liver and kidney function.

Ms Spencer said she was thrilled the hospital was taking part in "such an important study".

"The RUH is well-respected for its commitment to research and studies like these reflect our ongoing work to support vital medical trials which can help us better care for our patients now and in the future," she said.